StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregate of 37 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Next report date, year-over-year trend, and recent quarter history.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-22 | $44.61 | $44.96 | +0.78% | 10.8M |
| 05-26 | $44.74 | $44.19 | -1.23% | 9.4M |
| 05-27 | $44.18 | $44.55 | +0.84% | 11.3M |
| 05-28 | $44.05 | $45.51 | +3.31% | 14.6M |
| 05-29 | $45.48 | $45.58 | +0.22% | 11.0M |
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
6-factor scoring with sector-relative rank. Updated daily.
Each row shows where NVO sits in our scored universe today on a single observational measurement. P85 means NVO ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows NVO's percentile within the scored universe — observational ranking, not a recommendation.
No sell-side coverage available for NVO yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Fundamentals not available for NVO yet.
We pull from FMP, Finnhub, and Polygon — common gaps are very recent IPOs that haven't filed their first 10-Q, pink-sheet OTC tickers, and foreign filers without US-listed depth. The Financials tab reads SEC EDGAR directly and may still have data here.